Why must Shengli shares be reorganized?

Because under the condition of controlling listed companies with refinancing qualifications (or can be created through asset restructuring), as a major shareholder, it is easier to serve the holding company by determining the investment of raised funds; Secondly, its legal person shares can be mortgaged to banks to further obtain debt financing.

Company industry:

1, creator of victory

China 10 is the largest manufacturer of veterinary APIs, the world's largest manufacturer of tamycin and flavomycin, and the first manufacturer of tamycin API certified by the EU COS in China. The company's biological industry has two production bases in Jinan and Jining, with first-class equipment, advanced management and large-scale production capacity. Mainly engaged in the research, development, production and sales of veterinary raw materials and preparations. The products include termycin, enramycin, flavomycin, hainanmycin, avermectin, salinomycin, monensin and so on. Products have passed the GMP certification of the Ministry of Agriculture, sold well at home and abroad with healthy, safe and efficient quality, and ranked first in the country in export market share for many years. Shengli Bio is committed to the continuous updating of technology and services, and strives to build the first biotechnology enterprise in China.

2. Shengli Research Institute

Shandong Research Center for Animal-specific Antibiotics Engineering Technology, a platform for new drug creation cultivated in Shandong Province, and a postdoctoral workstation in Jinan High-tech Zone. Based on the biochemical engineering theory, the research institute of biochemistry and chemical engineering of the company focuses on developing three series of products: biological veterinary drugs, biological pesticides and biological preservatives by means of gene technology, fermentation technology, chemical synthesis and separation technology. After years of accumulation, it has formed a relatively perfect cooperation system and independent innovation capability in Industry-University-Research. With the help of modern industrial directional breeding platform and multi-scale microbial reaction process optimization platform, the efficiency of new drug research and development is greatly improved by using circulating protoplast fusion technology, recombinant enrichment technology and Qualcomm screening technology. Successfully developed new varieties such as hainanmycin, taimiaomycin, flavomycin, valnemulin, avilamycin and enramycin, which effectively promoted the technical progress and upgrading of the industry.